UBS AM’s Greenwich LifeSciences GLSI Stock Holding History

UBS AM’s Portfolio GLSI Stock Details GLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.2K	Hold	521	–	–	﹤0.01%	3225
2026 Q1	$12.5K	Buy	521 +328	+170%	+$8.55K	﹤0.01%	3260
2025 Q4	$4.05K	Buy	+193	New	+$2.03K	﹤0.01%	3018

Other funds holding GLSI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS AM's GLSI Position: Q2 2026 in Review

UBS AM held its Greenwich LifeSciences (GLSI) position steady in Q2 2026 at 521 shares worth $12.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3225.

UBS AM first reported a position in GLSI in Q4 2025 and has held it in 3 quarters since. The position peaked at $12.5K in Q1 2026. 58 funds tracked by Wall St. Rank hold GLSI as of Q2 2026.

UBS AM held 521 shares of Greenwich LifeSciences worth $12.2K as of Q2 2026.
UBS AM left its Greenwich LifeSciences share count unchanged in Q2 2026.
Greenwich LifeSciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3225 holding.
UBS AM first reported a position in Greenwich LifeSciences in Q4 2025 and has held it in 3 quarters since.
UBS AM's Greenwich LifeSciences position peaked at $12.5K in Q1 2026.
58 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.